OssDsign Catalyst becomes universally available to all Military Treatment Facilities in the U.S. via ECAT
OssDsign AB (publ.) today announces that the company’s nanosynthetic bone graft, OssDsign Catalyst has been included in the Department of Defense’s Military Health System’s electronic catalogue (ECAT), which means that the product is now universally available and can be ordered directly from any of the more than 50 Military Treatment Facilities in the U.S.
The uptake of OssDsign Catalyst in ECAT has been mediated through the previously communicated collaboration with Red One Medical, a private-sector scout of medical innovation for the Department of Veterans Affairs (VA) and the Department of Defense (DoD). Via the Distribution and Pricing Agreement (DAPA), American veterans and military members now have broader access to OssDsign Catalyst.
"We are very pleased that OssDsign Catalyst has been included in ECAT making our innovative nanosynthetic bone graft immediately available to all Military Treatment Facilities, independent of individual accounts with specific clinics. By broadening access to this important customer group, we take a vital step forward in penetrating the U.S. military market at the same time as we deepen our relationship with Red One Medical, Veterans Affairs, and Department of Defense,” said Morten Henneveld, CEO, of OssDsign.
“Red One Medical is proud to partner with OssDsign in order to provide innovative medical solutions for America’s military and veteran patients. OssDsign’s product portfolio provides advanced options to treat the specific needs of this patient population” said Charles Pollak, CEO, of Red One Medical.
OssDsign Catalyst is a nanosynthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion surgeries. The graft is composed of a proprietary nanocrystalline structure which is resorbed and replaced by new and healthy bone tissue. The product was launched in the U.S. in August 2021. The market clearance in the U.S. is based on preclinical results that surpass what is typically seen with other synthetic bone grafts in the most demanding preclinical model for spinal fusion - the Boden model. OssDsign continues to accelerate a robust program of gathering clinical evidence anchored by PROPEL, a U.S.-based multi-center prospective spinal fusion registry, and the clinical study TOP FUSION, in which patient enrolment was completed in April 2022. In September 2023, OssDsign Catalyst further received clearance for use in interbody cages in spinal surgery from the U.S. Food and Drug Administration (FDA), allowing surgeons to use OssDsign Catalyst on-label in any interbody cage cleared for use with synthetic bone grafts. OssDsign Catalyst is the first synthetic bone graft to be cleared to market for interbody use based on bone graft data alone.
Tags: